<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The NFκB-signaling pathway regulates cell proliferation and <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Activation of the pathway is implicated in the etiology of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="1" ids="35475">NSAIDs</z:chebi> may reduce <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> risk partially through a nuclear factor-kappa B (NFκB)-dependent pathway </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, we investigated associations between 34 NFκB1 and 8 IκBKβ tagSNPs and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> risk and examined interactions with <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drug</z:chebi> (<z:chebi fb="1" ids="35475">NSAID</z:chebi>) use </plain></SENT>
<SENT sid="4" pm="."><plain>Using conditional logistic regression, we investigated these associations among 1584 incident <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cases and 2516 sibling controls from the <z:hpo ids='HP_0003003'>Colon Cancer</z:hpo> Family Registry </plain></SENT>
<SENT sid="5" pm="."><plain>Three IκBKβ SNPs were associated with a statistically significant lower colorectal or <z:hpo ids='HP_0003003'>colon cancer</z:hpo> risk: rs9694958 (A&gt;G intron 5) (colorectal: OR(hzv) = 0.26(0.07-0.99), P(trend) = 0.048, P(adj) = 0.25), rs10958713 (A&gt;C intron 19) (colon: OR(hzv) = 0.62(0.42-0.92), P(trend) = 0.005, P(adj) = 0.03) and rs5029748 (C&gt;A intron 2) (colon: OR(het) = 0.72(0.56-0.91), P(trend) = 0.01, P(adj) = 0.08) </plain></SENT>
<SENT sid="6" pm="."><plain>We replicated trends associated with NFκB1 and IκBKβ variants identified in a previous study (rs4648110 (T&gt;A intron 22), rs13117745 (G&gt;A intron 5) and rs3747811 (T&gt;A intron 1)) </plain></SENT>
<SENT sid="7" pm="."><plain>IκBKβ's rs6474387 (C&gt;T intron 20) and rs11986055 (A&gt;C intron 2) showed substantially lower <z:hpo ids='HP_0003003'>colon cancer</z:hpo> risk among current <z:chebi fb="1" ids="35475">NSAID</z:chebi> users (P(interaction) = 0.01 and P(interaction) = 0.045, respectively), whereas NFκB1's rs230490 (G&gt;A 5' (outside UTR)) and rs997476 (C&gt;A 3' (outside UTR)) showed higher <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> risk among current <z:chebi fb="1" ids="35475">NSAID</z:chebi> users (P(interaction) = 0.01 and P(interaction) = 0.03, respectively) </plain></SENT>
<SENT sid="8" pm="."><plain>These findings suggest that variants in NFκB1 and IκBKβ are associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> risk and <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> may function partially through an NFκB-dependent pathway </plain></SENT>
<SENT sid="9" pm="."><plain>The SNPs identified here should be considered for future functional studies and may be useful in designing a pharmacogenetic approach to preventive <z:chebi fb="1" ids="35475">NSAID</z:chebi> use </plain></SENT>
</text></document>